Combination Chemotherapy for Metastatic Breast Cancer

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine the objective tumor response of the first-line therapy combination of gemcitabine and cisplatin in patients with metastatic breast cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Cisplatin; Gemcitabine

Criteria

Inclusion Criteria:

• You are female in the age of 18 to 75 years old.

• You have been diagnosed with the metastatic breast cancer.

• You have desire and an opportunity to visit your doctor in medical site, both during realization of the active treatment program, and within 24 months of medical follow up.

• You must sign this informed consent form

Exclusion Criteria:

• You are pregnant or breastfeeding.

• Your laboratory parameters fall outside the limits, admitted by requirements of the present clinical study.

• You have been diagnosed with serious concomitant or acute infectious disease.

• You have used experimental medications within the last month.